

PAGE: 1

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/320,157DATE: 03/17/95
TIME: 09:29:28

INPUT SET: S2805.raw

This Raw Listing contains the General
Information Section and up to the first 5 pages.

SEQUENCE LISTING

ENTERED

1
2
3 (1) General Information:
4
5 (i) APPLICANT: KIEFER, MICHAEL C.
6 BARR, PHILIP J.
7
8 (ii) TITLE OF INVENTION: NOVEL APOPTOSIS-MODULATING PROTEINS, DNA
9 ENCODING THE PROTEINS AND METHODS OF USE THEREOF
10
11 (iii) NUMBER OF SEQUENCES: 22
12
13 (iv) CORRESPONDENCE ADDRESS:
14 (A) ADDRESSEE: MORRISON & FOERSTER
15 (B) STREET: 755 Page Mill Road
16 (C) CITY: Palo Alto
17 (D) STATE: California
18 (E) COUNTRY: USA
19 (F) ZIP: 94304-1018
20
21 (v) COMPUTER READABLE FORM:
22 (A) MEDIUM TYPE: Floppy disk
23 (B) COMPUTER: IBM PC compatible
24 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
25 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
26
27 (vi) CURRENT APPLICATION DATA:
28 (A) APPLICATION NUMBER: US 08/320,157
29 (B) FILING DATE: 07-OCT-1994
30 (C) CLASSIFICATION:
31
32 (viii) ATTORNEY/AGENT INFORMATION:
33 (A) NAME: LEHNHARDT, SUSAN K.
34 (B) REGISTRATION NUMBER: 33,943
35 (C) REFERENCE/DOCKET NUMBER: 23647-20007.20
36
37 (ix) TELECOMMUNICATION INFORMATION:
38 (A) TELEPHONE: (415) 813-5600
39 (B) TELEFAX: (415) 494-0792
40 (C) TELEX: 706141
41
42
43 (2) INFORMATION FOR SEQ ID NO:1:
44
45 (i) SEQUENCE CHARACTERISTICS:
46 (A) LENGTH: 8 amino acids

RAW SEQUENCE LISTING
PATENT APPLICATION **US/08/320,157**DATE: 03/17/95
TIME: 09:29:32**INPUT SET: S2805.raw**

47 (B) TYPE: amino acid
48 (C) STRANDEDNESS: single
49 (D) TOPOLOGY: linear
50
51
52
53
54
55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
56
57 Asp Trp Gly Arg Val Val Ala Ile
58 1 5
59
60 (2) INFORMATION FOR SEQ ID NO:2:
61
62 (i) SEQUENCE CHARACTERISTICS:
63 (A) LENGTH: 36 base pairs
64 (B) TYPE: nucleic acid
65 (C) STRANDEDNESS: single
66 (D) TOPOLOGY: linear
67
68
69
70 (ix) FEATURE:
71 (A) NAME/KEY: misc_difference
72 (B) LOCATION: replace(23, "")
73 (D) OTHER INFORMATION: /note= "This position is inosine."
74
75 (ix) FEATURE:
76 (A) NAME/KEY: misc_difference
77 (B) LOCATION: replace(27, "")
78 (D) OTHER INFORMATION: /note= "This position is inosine."
79
80
81 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
82
83 AGATCTGAAT TCAACTTGGG GGNCAGNAGT NGTNCC 36
84
85 (2) INFORMATION FOR SEQ ID NO:3:
86
87 (i) SEQUENCE CHARACTERISTICS:
88 (A) LENGTH: 11 amino acids
89 (B) TYPE: amino acid
90 (C) STRANDEDNESS: single
91 (D) TOPOLOGY: linear
92
93
94
95
96
97 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
98
99 Asp Trp Gly Gly Gln Glu Asn Asp Gln Ile Trp

INPUT SET: S2805.raw

100 1 5 10

101

102 (2) INFORMATION FOR SEQ ID NO:4:

103

104 (i) SEQUENCE CHARACTERISTICS:

105 (A) LENGTH: 29 base pairs

106 (B) TYPE: nucleic acid

107 (C) STRANDEDNESS: single

108 (D) TOPOLOGY: linear

109

110

111

112 (ix) FEATURE:

113 (A) NAME/KEY: misc_difference

114 (B) LOCATION: replace(6, "")

115 (D) OTHER INFORMATION: /note= "This position is inosine."

116

117 (ix) FEATURE:

118 (A) NAME/KEY: misc_difference

119 (B) LOCATION: replace(9, "")

120 (D) OTHER INFORMATION: /note= "This position is inosine."

121

122

123 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

124

125 AGGGTNGGNG GNACNAGAGA CATCTAGGT 29

126

127 (2) INFORMATION FOR SEQ ID NO:5:

128

129 (i) SEQUENCE CHARACTERISTICS:

130 (A) LENGTH: 41 base pairs

131 (B) TYPE: nucleic acid

132 (C) STRANDEDNESS: single

133 (D) TOPOLOGY: linear

134

135

136

137 (ix) FEATURE:

138 (A) NAME/KEY: misc_difference

139 (B) LOCATION: replace(19, "")

140 (D) OTHER INFORMATION: /note= "This position is inosine."

141

142 (ix) FEATURE:

143 (A) NAME/KEY: misc_difference

144 (B) LOCATION: replace(22, "")

145 (D) OTHER INFORMATION: /note= "This position is inosine."

146

147

148 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

149

150 AGATCTAACG TTGTCCCANC CNCCNTGNTC CTTGAGATCC A 41

151

152 (2) INFORMATION FOR SEQ ID NO:6:

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/320,157DATE: 03/17/95
TIME: 09:29:38

INPUT SET: S2805.raw

153
 154 (i) SEQUENCE CHARACTERISTICS:
 155 (A) LENGTH: 2094 base pairs
 156 (B) TYPE: nucleic acid
 157 (C) STRANDEDNESS: single
 158 (D) TOPOLOGY: linear
 159
 160
 161
 162 (ix) FEATURE:
 163 (A) NAME/KEY: CDS
 164 (B) LOCATION: 201..833
 165
 166
 167 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
 168
 169 GAGGATCTAC AGGGGACAAG TAAAGGCTAC ATCCAGATGC CGGGAATGCA CTGACGCCCA 60
 170
 171 TTCCTGGAAA CTGGGCTCCC ACTCAGCCCC TGGGAGCAGC AGCCGCCAGC CCCTCGGACC 120
 172
 173 TCCATCTCCA CCCTGCTGAG CCACCCGGGT TGGGCCAGGA TCCCGGCAGG CTGATCCCGT 180
 174
 175 CCTCCACTGA GACCTGAAAA ATG GCT TCG GGG CAA GGC CCA GGT CCT CCC 230
 176 Met Ala Ser Gly Gln Gly Pro Gly Pro Pro
 177 1 5 10
 178
 179 AGG CAG GAG TGC GGA GAG CCT GCC CTG CCC TCT GCT TCT GAG GAG CAG 278
 180 Arg Gln Glu Cys Gly Glu Pro Ala Leu Pro Ser Ala Ser Glu Glu Gln
 181 15 20 25
 182
 183 GTA GCC CAG GAC ACA GAG GAG GTT TTC CGC AGC TAC GTT TTT TAC CGC 326
 184 Val Ala Gln Asp Thr Glu Glu Val Phe Arg Ser Tyr Val Phe Tyr Arg
 185 30 35 40
 186
 187 CAT CAG CAG GAA CAG GAG GCT GAA GGG GTG GCT GCC CCT GCC GAC CCA 374
 188 His Gln Gln Glu Gln Ala Glu Gly Val Ala Ala Pro Ala Asp Pro
 189 45 50 55
 190
 191 GAG ATG GTC ACC TTA CCT CTG CAA CCT AGC AGC ACC ATG GGG CAG GTG 422
 192 Glu Met Val Thr Leu Pro Leu Gln Pro Ser Ser Thr Met Gly Gln Val
 193 60 65 70
 194
 195 GGA CGG CAG CTC GCC ATC ATC GGG GAC GAC ATC AAC CGA CGC TAT GAC 470
 196 Gly Arg Gln Leu Ala Ile Ile Gly Asp Asp Ile Asn Arg Arg Tyr Asp
 197 75 80 85 90
 198
 199 TCA GAG TTC CAG ACC ATG TTG CAG CAC CTG CAG CCC ACG GCA GAG AAT 518
 200 Ser Glu Phe Gln Thr Met Leu Gln His Leu Gln Pro Thr Ala Glu Asn
 201 95 100 105
 202
 203 GCC TAT GAG TAC TTC ACC AAG ATT GCC ACC AGC CTG TTT GAG AGT GGC 566
 204 Ala Tyr Glu Tyr Phe Thr Lys Ile Ala Thr Ser Leu Phe Glu Ser Gly
 205 110 115 120

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/320,157DATE: 03/17/95
TIME: 09:29:42

INPUT SET: S2805.raw

206
207 ATC AAT TGG GGC CGT GTG GTG GCT CTT CTG GGC TTC GGC TAC CGT CTG 614
208 Ile Asn Trp Gly Arg Val Val Ala Leu Leu Gly Phe Gly Tyr Arg Leu
209 125 130 135
210
211 GCC CTA CAC GTC TAC CAG CAT GGC CTG ACT GGC TTC CTA GGC CAG GTG 662
212 Ala Leu His Val Tyr Gln His Gly Leu Thr Gly Phe Leu Gly Gln Val
213 140 145 150
214
215 ACC CGC TTC GTG GTC GAC TTC ATG CTG CAT CAC TGC ATT GCC CGG TGG 710
216 Thr Arg Phe Val Val Asp Phe Met Leu His His Cys Ile Ala Arg Trp
217 155 160 165 170
218
219 ATT GCA CAG AGG GGT GGC TGG GTG GCA GCC CTG AAC TTG GGC AAT GGT 758
220 Ile Ala Gln Arg Gly Gly Trp Val Ala Ala Leu Asn Leu Gly Asn Gly
221 175 180 185
222
223 CCC ATC CTG AAC GTG CTG GTG GTT CTG GGT GTG GTT CTG TTG GGC CAG 806
224 Pro Ile Leu Asn Val Leu Val Val Leu Gly Val Val Leu Leu Gly Gln
225 190 195 200
226
227 TTT GTG GTA CGA AGA TTC TTC AAA TCA TGACTCCCAA GGGTGCCCTT 853
228 Phe Val Val Arg Arg Phe Phe Lys Ser
229 205 210
230
231 TGGGTCCCGG TTCAGACCCC TGCCTGGACT TAAGCGAAGT CTTGCCTTC TCTGTTCCCT 913
232
233 TGCAGGGTCC CCCCTCAAGA GTACAGAACG TTTAGCAAGT GTGCACCTCCA GCTTCGGAGG 973
234
235 CCCTGCCTGG GGGCCAGTCA GGCTGCAGAG GCACCTCAAC ATTGCATGGT GCTAGTGCCTC 1033
236
237 TCTCTCTGGG CCCAGGGCTG TGGCCGTCTC CTCCCTCAGC TCTCTGGAC CTCCTTAGCC 1093
238
239 CTGTCTGCTA GGCGCTGGGG AGACTGATAA CTTGGGGAGG CAAGAGACTG GGAGCCACTT 1153
240
241 CTCCCCAGAA AGTGTAAAC GGTTTAGCT TTTTATAATA CCCTTGAG AGCCATTCC 1213
242
243 CACCATTCTA CCTGAGGCCA GGACGTCTGG GGTGTGGGA TTGGTGGTC TATGTTCCCC 1273
244
245 AGGATTCAGC TATTCTGGAA GATCAGCACC CTAAGAGATG GGACTAGGAC CTGAGCCTGG 1333
246
247 TCCTGCCGT CCCTAACCAT GTGTCCCAGG AGCAGGACCT ACTAGGAGAG GGGGGCCAAG 1393
248
249 GTCCTGCTCA ACTCTACCCC TGCTCCCATT CCTCCCTCCG GCCATACTGC CTTTGAGTT 1453
250
251 GGACTCTCAG GGATTCTGGG CTTGGGTGT GGGGTGGGT GGAGTCGCAG ACCAGAGCTG 1513
252
253 TCTGAACCTCA CGTGTCAAGAA GCCTCCAAGC CTGCCTCCCA AGGTCTCTC AGTTCTCTCC 1573
254
255 CTTCCCTCTCT CTTTATAGAC ACTTGCTCCC AACCCATTCA CTACAGGTGA AGGCTCTCAC 1633
256
257 CCATCCCTGG GGGCCTTGGG TGAGTGGCCT GCTAAGGCTC CTCCTTGCCC AGACTACAGG 1693
258

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

7. Other: _____

Applicant must provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

Please return a copy of this notice with your response.